Accucaps doubles production capacity in Ontario facility

By staff reporter

- Last updated on GMT

Related tags North america

Accucaps Industries, an encapsulation firm, has converted its
Strathroy, Ontario facility to focus on health and nutritional
(H&N) products, a move the firm says will double its total
production capacity.

According to the company, the facility will become the 'centre of excellence' for the manufacturing and production of H&N in North America, although it will also focus on cosmetics. Accucaps, a contract manufacturer for soft gelatin encapsulation, expects the Southwestern Ontario operation to allow it to offer certain advantages to its customers, including "shorter lead times, competitive pricing and dependable product quality". ​ The new facility, which is GMP and HHPD-licensed, has product compounding, 16 encapsulation machines capable of producing 4 billion doses, a large temperature-controlled warehouse, and capabilities for blistering, bottling and distribution, said the firm. The conversion of the 125,000 square foot facility will effectively double the total manufacturing and production capacity for Accucaps, it said. The company claims that its Strathroy and Windsor operations, which are registered with FDA and Health Canada, position it as the "single biggest"​ soft gel contract manufacturing organization serving the healthcare market in North America. "Accucaps is a customer-focused organization with a commitment to encapsulation excellence and developing powerful partnerships"​ said Peter Wares, director of sales and marketing in a statement. "Our strength in manufacturing and packaging a range of products that meet or exceed industry quality has allowed us to partner with our customers to supply products to markets in North America, South America, Europe, Asia, Australia and the Middle East,"​ he added. Europe​In 2006, Accucaps made its move into the European market, as part of a general global expansion, after being added to the bloc's consolidated list of approved suppliers. At the time, Denis Decarie, Accucaps' global business development manager, told NutraIngredients.com that entering this market would "alleviate the relative importance of the North American market on Accucaps.""We've worked hard to earn our reputation as a reliable company that delivers quality manufacturing,"​ said said Wares at the time. "This certification confirms that Accucaps is positioned to service the international marketplace and we look forward to the growth opportunities this approval from the EU affords us."

Related news

Related products

show more

Nextida: Precision where it matters

Nextida: Precision where it matters

Content provided by Rousselot | 09-May-2024 | Product Brochure

NEXTIDA™ is an innovative platform of specific collagen peptide compositions with new targeted health benefits. Built and backed by science, Nextida stands...

Optimize Nutritional Value with DuraLipo™

Optimize Nutritional Value with DuraLipo™

Content provided by INNOBIO Corporation Limited | 02-May-2024 | White Paper

INNOBIO's DuraLipo™ products encapsulates active ingredients within phospholipids, forming a genuine phospholipid bilayer structure.

HRB probiotics in the HMO era

HRB probiotics in the HMO era

Content provided by Morinaga Milk Industry Co., Ltd. | 29-Apr-2024 | White Paper

Discover the science behind human-residential bifidobacteria (HRB) probiotics and their superior benefits for infants.

Related suppliers

Follow us

Products

View more

Webinars